Researchers are reporting impressive results in a small, open-label trial of the JAK inhibitor tofacitinib in cutaneous sarcoidosis: 6 of 10 patients improved so much that they reached a disease activity...

Low blood levels of immune cells called lymphocytes, in combination with higher levels of inflammation on PET/CT scans, are indicators of active sarcoidosis — an inflammatory disease that attacks...